Predictive Oncology, Augmedix, Cue Health Among Healthcare Movers
Express News | Sight Sciences Announces the Publication of Twelve-Month Results of the Sahara Rct Demonstrating Improved Signs and Symptoms of Dry Eye Disease for Tearcare Patients Crossed Over From Restasis
Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating...
Sight Sciences' Study Of OMNI System In Advanced Glaucoma Reports Positive Outcome
Sight Sciences Published Results Of ROMEO Study Data In Journal Clinical Opthalmology.
Sight Sciences Published Results Of ROMEO Study Data In Journal Clinical Opthalmology.
Sight Sciences Announces Publication of a New Analysis From The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved With OMNI Across Mild, Moderate, and Advanced Glaucoma
MENLO PARK, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing
Sight Sciences(SGHT.US) Officer Sells US$70,869.98 in Common Stock
$Sight Sciences(SGHT.US)$ Officer Bauerlein Alison sold 13,066 shares of common stock on May 17, 2024 at an average price of $5.424 for a total value of $70,869.98.Source: Announcement What is stateme
Sight Sciences to Present at the Upcoming Bank of America Healthcare Conference
MENLO PARK, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing
Sight Sciences | 10-Q: Quarterly report
Sight Sciences, Inc. (NASDAQ:SGHT) Analysts Are Pretty Bullish On The Stock After Recent Results
Shareholders of Sight Sciences, Inc. (NASDAQ:SGHT) will be pleased this week, given that the stock price is up 13% to US$5.96 following its latest first-quarter results. Revenue of US$19m came i
Earnings Call Summary | Sight Sciences(SGHT.US) Q1 2024 Earnings Conference
The following is a summary of the Sight Sciences, Inc. (SGHT) Q1 2024 Earnings Call Transcript:Financial Performance:Sight Sciences reported Q1 2024 revenue of $19.3 million, a record for their first
Sight Sciences First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Sight Sciences Shares Up After Q1 Net Loss Narrows, Revenue Rises; 2024 Revenue Outlook Reaffirmed
Sight Sciences (SGHT) shares were up nearly 4%, a day after the company reported narrower Q1 loss and revenue that exceeded consensus. The company reported Q1 net loss Thursday of $0.33 per diluted sh
Piper Sandler: Reiterates the Sight Sciences (SGHT.US) rating, adjusted from neutral to neutral, and adjusted the target price from $5.00 to $6.00.
Piper Sandler: Reiterates the Sight Sciences (SGHT.US) rating, adjusted from neutral to neutral, and adjusted the target price from $5.00 to $6.00.
Piper Sandler Reiterates Neutral on Sight Sciences, Raises Price Target to $6
Piper Sandler analyst Matt O'Brien reiterates Sight Sciences (NASDAQ:SGHT) with a Neutral and raises the price target from $5 to $6.
Piper Sandler Sticks to Their Hold Rating for Sight Sciences (SGHT)
Needham Remains a Hold on Sight Sciences (SGHT)
Sight Sciences Q1 2024 GAAP EPS $(0.33) Misses $(0.30) Estimate, Sales $19.265M Beat $18.382M Estimate
Sight Sciences (NASDAQ:SGHT) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.30) by 10 percent. This is a 5.71 percent increase over losses of $(0.35)
Earnings Flash (SGHT) SIGHT SCIENCES Reports Q1 Revenue $19.3M, Vs. Street Est of $18.4M
04:29 PM EDT, 05/02/2024 (MT Newswires) -- Earnings Flash (SGHT) SIGHT SCIENCES Reports Q1 Revenue $19.3M, vs. Street Est of $18.4M
Sight Sciences Enhances Transparency With Strategic Financial Moves
No Data